InVitae's 'Long, Uncertain Path' Toward Profitability: Analyst Downgrades Biotech
Shares of Invitae Corp (NYSE: NVTA) came under pressure on Monday, after gaining more than 24% in January.
Despite having a restricting plan in place, the biotech company has a “long path to profitability,” according to Goldman Sachs.
